Posted On: Sunday, February 21st, 2016
We are pleased to announce the launch of the solicitation of Letters of Intent for the Public Health Agency of Canada’s HIV and Hepatitis C Community Action Fund (Community Action Fund). Thanks to your continued engagement and valuable input over the past year, we have developed our approach to the Community Action Fund by considering… Read more »
Posted On: Tuesday, February 9th, 2016
Thank you for your continued patience and input throughout the public procurement process. For your information the PHSA HIV & HCV Prevention, Care and Treatment Services request for proposals has now been posted on BC Bid. Please follow the steps below to download the RFP: · Go to http://www.bcbid.gov.bc.ca/open.dll/welcome?language=En · Click on ‘Browse for Bid… Read more »
Posted On: Sunday, November 22nd, 2015
CATIE’s Hepatitis C Ethnocultural Education, Outreach and Social Marketing Program works with immigrants and newcomers to develop accessible Hep C resources in multiple languages. Learn more about how the program builds partnerships with community-based organizations to offer information in the languages spoken in newcomer communities. Read about CATIE’s hepatitis C awareness program for immigrants and… Read more »
Posted On: Monday, November 9th, 2015
This fall Daryl Luster, PHCN’s president, has been moonlighting as a blog writer. He has been using his knowledge and experience with hep C to be a strong voice for those with the disease. His blog posts have been published online by HepatitisC.net. Blog Posts Written by Daryl for HepatitisC.net Care, and the Trust in… Read more »
Posted On: Monday, November 9th, 2015
In Canada and most other high-income countries today, standard treatment for people who have genotype 1 infection with hepatitis C virus (HCV) includes combinations of medicines called direct-acting antivirals (DAAs). These are medicines that are taken orally, every day, usually for 12 to 24 consecutive weeks. In large clinical trials, treatment with modern DAAs—such as… Read more »
Posted On: Monday, November 2nd, 2015
New and Noteworthy People who inject drugs should have access to hepatitis C treatment, expert panel recommends New guidelines for the management of Hep C in people who inject drugs encourage offering treatment to people who inject drugs, reported researchers in the International Journal of Harm Reduction Policy. The recommendations were developed by an international… Read more »
Posted On: Monday, October 26th, 2015
The Canadian Agency for Drugs and Technologies in Health (CADTH) wants to hear from you! They are currently seeking patient input for grazoprevir / elbasvir and, therefore, the Pacific Hep C Network (PHCN) needs your thoughts, opinions, and experiences for our patient group input report. There are two PHCN Input Surveys Take this survey if… Read more »
Posted On: Monday, October 19th, 2015
The CIHR HIV/AIDS Research Initiative along with its Partners will be hosting a webinar on Friday, October 30th from 12:30pm – 2:00pm EST to discuss the recently launched Implementation Science for the Prevention of HIV, HCV and STBBIs – Component 1: Adaptation Grants Funding Opportunity. Click here to register. The webinar will focus on: • A… Read more »
Posted On: Monday, October 19th, 2015
New and Noteworthy High cure rates for people on opiate substitution therapy with Holkira Pak A small, mid-stage clinical trial of participants on opioid substitution therapy (OST) who took Holkira Pak and ribavirin for 12 weeks had a cure rate of 97% reported researchers in the Journal of Hepatology. OST is taken by people who… Read more »
Posted On: Tuesday, October 13th, 2015
The World Health Organization/Pan-American Health Organization Action Plan for the Prevention and Control of Viral Hepatitis was approved last week during the 67th Session of the Regional Committee of WHO for the Americas in Washington, DC! The new plan not only lays out steps to reduce illnesses and deaths due to hepatitis, but also sets… Read more »
Posted On: Sunday, September 27th, 2015
New and Noteworthy Daclatasvir approved in Canada The Hep C drug daclatasvir (Daklinza) has been approved in Canada for people with genotype 1 or 2 virus. It has also been conditionally approved for people with genotype 3 virus pending the outcome of a late-stage clinical trial. Daclatasvir is taken with sofosbuvir (Sovaldi) for 12 weeks… Read more »
Posted On: Tuesday, September 22nd, 2015
